EP Patent

EP4427814A3 — Controlled release peptide formulations

Assigned to Camurus AB · Expires 2024-11-20 · 1y expired

What this patent protects

The present invention relates to compositions forming a low viscosity mixture of:a) 20-80 wt.% of at least one diacyl glycerol and/or a tocopherol;b) 20-80 wt.% of at least one phosphatidyl choline (PC);c) 5-20 wt.% of at least one biocompatible, organic mono-alcoholic solvent;d)…

USPTO Abstract

The present invention relates to compositions forming a low viscosity mixture of:a) 20-80 wt.% of at least one diacyl glycerol and/or a tocopherol;b) 20-80 wt.% of at least one phosphatidyl choline (PC);c) 5-20 wt.% of at least one biocompatible, organic mono-alcoholic solvent;d) up to 20 wt.% polar solvente) at least one peptide active agent;f) optionally at least one antioxidant;wherein the ratio of components a:b is in the range 40:60 to 54:46;wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

Drugs covered by this patent

Patent Metadata

Patent number
EP4427814A3
Jurisdiction
EP
Classification
—
Expires
2024-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Camurus AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.